EIOC Journal Club: Virtual Round Table Discussion

Topic: Immunotherapy and New NSCLC Pipeline

Abstract:

Immunotherapy in non-small cell lung cancer (NSCLC) is a treatment approach that leverages the patient's own immune system to fight the cancer, primarily through immune checkpoint inhibitors (ICIs) like anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies. These therapies work by blocking "checkpoint proteins" that prevent T-cells from recognizing and attacking cancer cells. ICIs are now used across various stages of NSCLC, including first-line therapy for advanced disease, consolidation therapy for unresectable locally advanced disease, and adjuvant therapy after surgery.

In this round table discussion, we will discuss the potential topics listed as below,

•           Innovations in mNSCLC: Emerging Data and Breakthroughs

•        New Horizons in Immunotherapy

Ø  Overview of the evolving role of immunotherapy in mNSCLC

Ø  Key clinical trial updates (Cemiplimab, Tremelimumab…etc)

Ø  Biomarker-driven patient selection strategies

•           Monotherapy and Combination therapy strategies

•        Antibody-Drug Conjugates (ADCs): Targeted Precision Medicine